Beschreibung:
<jats:title>ABSTRACT</jats:title>
<jats:p>
Thiram and disulfiram were evaluated as antibacterial agents against multidrug-resistant
<jats:named-content content-type="genus-species">Staphylococcus aureus</jats:named-content>
. Against a 30-member panel comprised of vancomycin-susceptible, vancomycin-intermediate, and vancomycin-resistant
<jats:named-content content-type="genus-species">S. aureus</jats:named-content>
strains, the MIC
<jats:sub>90</jats:sub>
values of the respective test agents were 4 and 16 μg/ml. Additional analyses revealed that thiram and disulfiram are rapid-acting bacteriostatic agents with narrow, Gram-positive-bacterium spectrum activity. Synergy studies further determined that disulfiram increases the vancomycin susceptibility of three clinical vancomycin-resistant
<jats:named-content content-type="genus-species">S. aureus</jats:named-content>
strains
<jats:italic>in vitro</jats:italic>
, thus establishing a potential use in combination therapy.
</jats:p>